Supernus Pharmaceuticals Inc

자세한 내용은 Supernus Pharmaceuticals Inc 회사

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson’s Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Supernus Pharmaceuticals Inc 정보



종목 코드 SUPN

회사 이름Supernus Pharmaceuticals Inc

상장일Dec 28, 2010

CEOMr. Jack A. Khattar

직원 수674

유형Ordinary Share

회계 연도 종료Dec 28

주소9715 Key West Avenue

도시ROCKVILLE

증권 거래소NASDAQ Global Market Consolidated

국가United States of America

우편 번호20850

전화13018382500

웹사이트https://www.supernus.com

종목 코드 SUPN

상장일Dec 28, 2010

CEOMr. Jack A. Khattar

Supernus Pharmaceuticals Inc의 회사 임원진



이름

이름/직위

직위

주식 보유

변동

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.21M

+2.76%

Mr. Frederick M. Hudson, CPA

Independent Director

46.31K

-13.87%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

15.15K

--

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

13.37K

+5.27%

Dr. Jonathan Rubin, M.D.

Senior Vice President, Chief Medical Officer - Research and Development

10.67K

+10.74%

Mr. Timothy C. (Tim) Dec, CPA

Chief Financial Officer, Senior Vice President

901.00

-92.89%

Mr. Charles W. Newhall, III

Independent Chairman of the Board

--

Ms. Bethany L. Sensenig

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Jack A. Khattar

President, Chief Executive Officer, Secretary, Director

2.21M

+2.76%

Mr. Frederick M. Hudson, CPA

Independent Director

46.31K

-13.87%

Dr. Carrolee Barlow, M.D., Ph.D.

Independent Director

22.57K

--

Dr. Georges Gemayel, Ph.D.

Independent Director

18.68K

--

Mr. Frank Mottola

Chief Operating Officer, Chief Technology Officer

15.15K

--

Dr. Padmanabh P. Bhatt, Ph.D.

Senior Vice President - Intellectual Property, Chief Scientific Officer

13.37K

+5.27%

수익 분석

통화: USD마지막 업데이트: Mon, Oct 6

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Net product sales-Qelbree

77.55M

46.87%

Net product sales - GOCOVRI

36.66M

22.16%

Net product sales-APOKYN

12.82M

7.75%

Net product sales- Oxtellar XR

11.64M

7.03%

Net product sales- Trokendi XR

11.19M

6.77%

기타

15.60M

9.43%

지역별USD

이름

수익

비율

United States

165.45M

100.00%

사업별

지역별

사업별USD

이름

수익

비율

Net product sales-Qelbree

77.55M

46.87%

Net product sales - GOCOVRI

36.66M

22.16%

Net product sales-APOKYN

12.82M

7.75%

Net product sales- Oxtellar XR

11.64M

7.03%

Net product sales- Trokendi XR

11.19M

6.77%

기타

15.60M

9.43%

주식 보유 통계

마지막 업데이트: Fri, Aug 15

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

13.97%

The Vanguard Group, Inc.

10.52%

Armistice Capital LLC

8.39%

Dimensional Fund Advisors, L.P.

5.27%

Macquarie Investment Management

4.82%

기타

57.03%

주주

비율

BlackRock Institutional Trust Company, N.A.

13.97%

The Vanguard Group, Inc.

10.52%

Armistice Capital LLC

8.39%

Dimensional Fund Advisors, L.P.

5.27%

Macquarie Investment Management

4.82%

기타

57.03%

주주 유형

주주

비율

Investment Advisor

52.68%

Investment Advisor/Hedge Fund

29.42%

Hedge Fund

17.15%

Individual Investor

4.28%

Research Firm

2.30%

Pension Fund

1.59%

Venture Capital

1.47%

Bank and Trust

0.67%

Sovereign Wealth Fund

0.10%

기관 주식 보유



마지막 업데이트: Wed, Oct 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q3

575

60.19M

104.97%

-3.36M

2025Q2

565

63.61M

113.46%

-2.51M

2025Q1

587

64.77M

115.71%

-2.86M

2024Q4

569

65.17M

116.92%

-2.59M

2024Q3

551

65.02M

117.72%

-2.14M

2024Q2

536

63.49M

115.33%

-2.27M

2024Q1

535

61.47M

111.83%

-3.83M

2023Q4

534

61.60M

112.54%

-3.30M

2023Q3

534

60.88M

111.42%

-4.46M

2023Q2

534

61.11M

111.93%

-1.60M

주주 활동



이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

8.01M

14.29%

-191.39K

-2.33%

Jun 30, 2025

The Vanguard Group, Inc.

6.19M

11.04%

+41.36K

+0.67%

Jun 30, 2025

Armistice Capital LLC

4.81M

8.58%

-384.00K

-7.39%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

3.02M

5.39%

+117.48K

+4.05%

Jun 30, 2025

Macquarie Investment Management

2.76M

4.93%

+62.46K

+2.31%

Jun 30, 2025

Khattar (Jack A)

2.15M

3.84%

+54.63K

+2.60%

Sep 30, 2025

State Street Investment Management (US)

2.21M

3.94%

+63.21K

+2.95%

Jun 30, 2025

Renaissance Technologies LLC

1.66M

2.95%

+69.60K

+4.39%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.40M

2.5%

+72.99K

+5.50%

Jun 30, 2025

Stephens Investment Management Group, LLC

1.58M

2.82%

-157.39K

-9.05%

Jun 30, 2025

주식 배당금



지난 5년 동안 총 0.00 USD의 배당금이 분배되었습니다.

날짜

배당금

기준일

지급일

배당락일

데이터 없음

주식 분할



날짜

유형

비율

데이터 없음

날짜

유형

비율

데이터 없음

자세한 내용은 Supernus Pharmaceuticals Inc 회사

Supernus Pharmaceuticals Inc 정보

Supernus Pharmaceuticals Inc의 회사 임원진

수익 분석

주식 보유 통계

기관 주식 보유

주주 활동

관련 ETF

주식 배당금

주식 분할